The ninth batch of presidential candidate Hillary Clinton’s emails released by WikiLeaks has some biopharma gossip that includes Clinton’s team discussing the FDA’s commissioner and it’s so-called “war on pharma.”
A study found that Pfizer’s Michigan manufacturing facility impacts Kalamazoo and Van Buren counties to the tune of about $2.2 billion.
One tweet. That is all it took from U.S. Senator Bernie Sanders to cause shares of Ariad Pharmaceuticals to drop 15 percent.
For this annual special report, which is in its 30th year of publication, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.
The amount of new drug approvals in 2015 was the FDA’s highest total since 1950 due in part to revamped pipelines, but a tough future looms as the grumblings over pricing have risen to a roar.
Health might be its own reward, but even cash incentives only work in the short term to motivate people to exercise more and activity trackers add little benefit, according to a study from Singapore.
Scientists launched a global initiative to map out and describe every cell in the human body in a vast atlas that could transform research.
AbbVie Inc. won the conditional backing of an advisory committee of the European Medicines Agency (EMA) for a drug to treat a form of blood cancer.
Drugmaker Intercept Pharmaceuticals Inc.’s drug to treat a rare liver condition was conditionally approved an advisory committee to the European Medicines Agency.
Riding high off of positive Phase III data for its PARP inhibitor niraparib, Tesaro Inc. is not looking for anyone to burst its bubble, including Myriad Genetics, which developed the companion diagnostic test Tesaro used in the Phase III trial.
TG Therapeutics stock took a dive on news that it was modifying the protocols in its Phase III clinical trial of TG-1101 for relapsed/refractory high-risk chronic lymphocytic leukemia (CLL).
Just a few years after its spin-off from Abbott, Med Ad News Company of the Year AbbVie is very much back in the big pharma conversation.
Amgen has focused the company’s business and operating model through significant transformation and process improvement efforts to produce innovative medicines while generating satisfactory investor returns.
AstraZeneca continues to rely on its growth platforms to bring the company back on track, weathering patent expirations as it cultivates the pipeline with many promising products.
U.S. death rates from breast cancer have dropped, although the decline was still greater among white women than black women, according to a study.
Britain’s healthcare cost agency NICE plans to fast-track its recommendations for the most cost-effective new drugs.
Immunotherapy, which boosts the immune system to fight cancer, could be the next big opportunity for Genmab, potentially driving peak sales of its top-selling drug well past $10 billion a year, its chief executive believes.
Health authorities worldwide need to move much faster to prevent, detect and treat a “deadly epidemic” of tuberculosis if they are to reduce TB infections and deaths by 2030, the World Health Organization warned.
Pfizer suffered a setback in Britain when the Court of Appeal in London ruled against it in a patent case over the use of its $5 billion-a-year drug Lyrica for pain relief.
Verily, Google’s life sciences division, aims to eliminate the threat of the mosquito-borne Zika virus by figuring out how to prevent the pesky pests from reproducing.